ArticleDiabetology international2016
Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus.
Article in Diabetology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsOur purpose was to clarify the predictive clinical characteristics of add-on therapy using dapagliflozin in patients with type 2 diabetes mellitus.
methodsThis single-center, open-label, pilot study was conducted in 50 patients with type 2 diabetes mellitus. They were treated with 50 mg dapagliflozin, once daily. A total of 46 patients were successfully followed over 12 weeks of treatment with dapagliflozin. They were assessed for several clinical parameters before the start of the study and at 12 weeks. Multiple linear regression analysis was used to search for independent predictors of reduction of hemoglobin A1c (HbA1c) levels after 12 weeks of dapagliflozin add-on treatment (ΔHbA1c).
resultsDapagliflozin administration for 12 weeks resulted in significant reductions in baseline body mass index, systolic blood pressure, fasting plasma glucose, HbA1c, alanine aminotransferase, and uric acid. We were also able to show that HbA1c levels and low-density lipoprotein cholesterol (LDL-C) significantly correlated with ΔHbA1c. Furthermore, multiple linear regression analysis showed that baseline HbA1c and LDL-C significantly correlated with ΔHbA1c.
conclusionOur prospective 12-week study showed that baseline HbA1c and LDL-C significantly contribute to the HbA1c-lowering effect of dapagliflozin.
trial registrationUMIN Clinical Trials Registry (UMIN000014922).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.